We are conducting a Phase 1 trial for SCB-219M, an innovative human thrombopoietin receptor agonist (TPO-RA), for the treatment of chemotherapy-induced thrombocytopenia (CIT). CIT is a serious, chemotherapy-associated complication observed in a wide range of cancer patients that can have detrimental impacts on treatment outcomes and can result in chemotherapy dose delay or dose reduction, and potentially fatal bleeding events.
We also developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. We believe SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis.
